Who Owns REGENXBIO Stock?
NASDAQ: RGNXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 65.26%
- Held by insiders
- 6.55%
- Institutional holders
- 232
- Institutions 65.3%
- Insiders 6.5%
- Public and other 28.2%
Who owns REGENXBIO stock?
Institutional investors own about 65.3% of REGENXBIO's shares, spread across 232 institutions that file 13F reports. That level of institutional ownership is moderate. Insiders, including executives, directors and large founding shareholders, hold 6.55% of RGNX.
The largest institutional holders are Blackrock Inc. (9.69%), Redmile Group, LLC (6.62%) and State Street Corporation (4.50%). Together, the top 10 institutions control 38.5% of shares outstanding. In their latest filings, 6 of the top 10 institutions increased their RGNX positions and 3 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of RGNX
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Blackrock Inc. | 6.40M | 9.69% | +10.6% |
| Redmile Group, LLC | 4.37M | 6.62% | 0.0% |
| State Street Corporation | 2.97M | 4.50% | +8.8% |
| JPMORGAN CHASE & CO | 2.21M | 3.35% | -36.4% |
| Vanguard Capital Management LLC | 2.11M | 3.19% | +5.0% |
| Morgan Stanley | 1.95M | 2.96% | -5.5% |
| Goldman Sachs Group Inc | 1.42M | 2.15% | -22.7% |
| AQR Capital Management, LLC | 1.38M | 2.09% | +31.1% |
| Vanguard Portfolio Management LLC | 1.36M | 2.05% | +33.0% |
| Marshall Wace LLP | 1.28M | 1.95% | +100.0% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of RGNX
| Fund | Shares | % Held |
|---|---|---|
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.07M | 3.13% |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.50M | 2.27% |
| iShares Trust-iShares Russell 2000 ETF | 1.25M | 1.90% |
| TIAA-CREF Funds-Nuveen Quant Small Cap Equity Fund | 855.17K | 1.30% |
| JPMorgan Trust II-JPMorgan Small Cap Growth Fund | 629.84K | 0.95% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 564.48K | 0.86% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 527.93K | 0.80% |
| VANGUARD HORIZON FUNDS-Vanguard Strategic Small-Cap Equity Fund | 467.25K | 0.71% |
| iShares Trust-iShares Biotechnology ETF | 441.44K | 0.67% |
| iShares Trust-iShares Russell 2000 Growth ETF | 381.02K | 0.58% |
Frequently asked questions
Who is the largest shareholder of REGENXBIO?
Blackrock Inc. is the largest institutional shareholder of RGNX, owning 9.69% of shares outstanding (6.40M shares) as of its latest 13F filing.
What percentage of REGENXBIO is owned by institutions?
Institutions own about 65.3% of RGNX shares and 69.8% of the public float.
How much of REGENXBIO do insiders own?
Insiders, such as officers and directors, own about 6.55% of RGNX shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.